Jun. 22 at 9:03 PM
$GNOM possesses strong structural potential to outperform the S&P 500 over the next few years.
While many popular ETFs have rallied hard this year, most are trading near all-time highs (ATHs).
In contrast, this genomics and biotech play remains near historical lows (ATLs).
Looking forward, this significant valuation reset offers a highly asymmetric risk-reward setup for mean reversion.